BRENDA - Enzyme Database show

Inhibition of Mycobacterium tuberculosis dihydrodipicolinate synthase by alpha-ketopimelic acid and its other structural analogues

Shrivastava, P.; Navratna, V.; Silla, Y.; Dewangan, R.P.; Pramanik, A.; Chaudhary, S.; Rayasam, G.; Kumar, A.; Gopal, B.; Ramachandran, S.; Sci. Rep. 6, 30827 (2016)

Data extracted from this reference:

Cloned(Commentary)
EC Number
Commentary
Organism
1.17.1.8
the dapB open reading frame is cloned in the expression vector pET28a for expression as N-terminal 6x His-tagged protein
Mycobacterium tuberculosis
4.3.3.7
the dapA open reading frame is cloned in the expression vector pET28a for expression as N-terminal 6 x His-tagged protein
Mycobacterium tuberculosis
Crystallization (Commentary)
EC Number
Crystallization
Organism
4.3.3.7
micro-batch method and hanging drop vapour diffusion methods of crystallization
Mycobacterium tuberculosis
Inhibitors
EC Number
Inhibitors
Commentary
Organism
Structure
4.3.3.7
2-(4-carbamoylphenyl)-2-oxoacetic acid
maximal inhibition of 15% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-hydroxyheptanediamide
maximal inhibition of 21% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-hydroxyheptanedioic acid
maximal inhibition of 74% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-oxohexanedioic acid
maximal inhibition of 40% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-oxopentanedioic acid
maximal inhibition of 15% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-oxopimelate
maximal inhibition of 88% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase. This assay is able to measure DapA enzyme kinetics if the dihydrodipicolinate reductase DapB is present in excess, because under these conditions DapA becomes rate limiting
Mycobacterium tuberculosis
4.3.3.7
2-phenoxyacetic acid
maximal inhibition of 4% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-((2-amino-2-oxoethyl)sulfonyl) butanoic acid
maximal inhibition of 29% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-((2-amino-2-oxoethyl)thio)butanoic acid
maximal inhibition of 15% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-(2,4,5-trioxoimidazolidin-1-yl)butanoic acid
maximal inhibition of 21% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-amino benzoic acid
maximal inhibition of 8% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-amino-2-hydroxybenzoic acid
maximal inhibition of 4% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-[amino(oxo)acetyl]benzoic acid
maximal inhibition of 34% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-[carboxy(hydroxy)methyl]benzoic acid
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-[methyl(oxalo)amino]butanoic acid
maximal inhibition of 39% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
5-(carbamoylamino)-5-oxopentanoic acid
maximal inhibition of 40% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
5-(carbamoylthio)pentanoic acid
maximal inhibition of 65% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
5-butylpyridine-2-carboxylic acid
maximal inhibition of 5% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
7-ethoxy-6,7-dioxoheptanoic acid
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
Benzoic acid
maximal inhibition of 2% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
carboxycarbonyl-benzoic acid
maximal inhibition of 22% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 4-((2-amino-2-oxoethyl)sulfinyl)butanoate
maximal inhibition of 31% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 4-((2-amino-2-oxoethyl)sulfonyl)butanoate
maximal inhibition of 12% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 4-((2-amino-2-oxoethyl)thio)butanoate
maximal inhibition of 21% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 5-(carbamoylsulfanyl)pentanoate
maximal inhibition of 34% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl [(4-amino-4-oxobutyl)(methyl)amino](oxo)acetate
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
heptanedioic acid
maximal inhibition of 10% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
hydroxy[4-(methoxycarbonyl)phenyl]acetic acid
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methoxycarbonyl-phenyloxoacetic acid
maximal inhibition of 29% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 3-oxohexanoate
maximal inhibition of 5% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 4-(2,4,5-trioxoimidazolidin-1-yl)butanoate
maximal inhibition of 38% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 4-[(2-ethoxy-2-oxoethyl)(methyl)amino]butanoate
maximal inhibition of 42% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 4-[amino(oxo)acetyl]benzoate
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 5-(carbamoylamino)-5-oxopentanoate
maximal inhibition of 65% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 6-oxo-6-(2H-tetrazol-5-yl)hexanoate
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 7-amino-6,7-dioxoheptanoate
maximal inhibition of 24% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 7-amino-6-hydroxy-7-oxoheptanoate
maximal inhibition of 28% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
additional information
molecular descriptors analysis shows that ligands with polar surface area of 91.7 A are likely inhibitors
Mycobacterium tuberculosis
4.3.3.7
N1-(4-amino-4-oxobutyl)-N1-methylethanediamide
maximal inhibition of 40% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
[(4-amino-4-oxobutyl)(methyl)amino](oxo)acetic acid
maximal inhibition of 44% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
Organism
EC Number
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
1.17.1.8
Mycobacterium tuberculosis
P9WP23
-
-
1.17.1.8
Mycobacterium tuberculosis H37Rv
P9WP23
-
-
4.3.3.7
Mycobacterium tuberculosis
P9WP25
-
-
4.3.3.7
Mycobacterium tuberculosis H37Rv
P9WP25
-
-
Purification (Commentary)
EC Number
Commentary
Organism
4.3.3.7
-
Mycobacterium tuberculosis
Substrates and Products (Substrate)
EC Number
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
1.17.1.8
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + NADPH + H+
-
746457
Mycobacterium tuberculosis
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + NADP+ + H2O
-
-
-
?
1.17.1.8
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + NADPH + H+
-
746457
Mycobacterium tuberculosis H37Rv
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + NADP+ + H2O
-
-
-
?
4.3.3.7
pyruvate + L-aspartate-4-semialdehyde
-
746457
Mycobacterium tuberculosis
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + H2O
-
-
-
?
4.3.3.7
pyruvate + L-aspartate-4-semialdehyde
-
746457
Mycobacterium tuberculosis H37Rv
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + H2O
-
-
-
?
Ki Value [mM]
EC Number
Ki Value [mM]
Ki Value maximum [mM]
Inhibitor
Commentary
Organism
Structure
4.3.3.7
0.021
-
2-oxopimelate
pH 7.4, 37C
Mycobacterium tuberculosis
IC50 Value
EC Number
IC50 Value
IC50 Value Maximum
Commentary
Organism
Inhibitor
Structure
4.3.3.7
0.0325
-
pH 7.4, 37C
Mycobacterium tuberculosis
2-oxopimelate
Cloned(Commentary) (protein specific)
EC Number
Commentary
Organism
1.17.1.8
the dapB open reading frame is cloned in the expression vector pET28a for expression as N-terminal 6x His-tagged protein
Mycobacterium tuberculosis
4.3.3.7
the dapA open reading frame is cloned in the expression vector pET28a for expression as N-terminal 6 x His-tagged protein
Mycobacterium tuberculosis
Crystallization (Commentary) (protein specific)
EC Number
Crystallization
Organism
4.3.3.7
micro-batch method and hanging drop vapour diffusion methods of crystallization
Mycobacterium tuberculosis
IC50 Value (protein specific)
EC Number
IC50 Value
IC50 Value Maximum
Commentary
Organism
Inhibitor
Structure
4.3.3.7
0.0325
-
pH 7.4, 37C
Mycobacterium tuberculosis
2-oxopimelate
Inhibitors (protein specific)
EC Number
Inhibitors
Commentary
Organism
Structure
4.3.3.7
2-(4-carbamoylphenyl)-2-oxoacetic acid
maximal inhibition of 15% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-hydroxyheptanediamide
maximal inhibition of 21% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-hydroxyheptanedioic acid
maximal inhibition of 74% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-oxohexanedioic acid
maximal inhibition of 40% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-oxopentanedioic acid
maximal inhibition of 15% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
2-oxopimelate
maximal inhibition of 88% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase. This assay is able to measure DapA enzyme kinetics if the dihydrodipicolinate reductase DapB is present in excess, because under these conditions DapA becomes rate limiting
Mycobacterium tuberculosis
4.3.3.7
2-phenoxyacetic acid
maximal inhibition of 4% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-((2-amino-2-oxoethyl)sulfonyl) butanoic acid
maximal inhibition of 29% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-((2-amino-2-oxoethyl)thio)butanoic acid
maximal inhibition of 15% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-(2,4,5-trioxoimidazolidin-1-yl)butanoic acid
maximal inhibition of 21% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-amino benzoic acid
maximal inhibition of 8% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-amino-2-hydroxybenzoic acid
maximal inhibition of 4% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-[amino(oxo)acetyl]benzoic acid
maximal inhibition of 34% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-[carboxy(hydroxy)methyl]benzoic acid
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
4-[methyl(oxalo)amino]butanoic acid
maximal inhibition of 39% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
5-(carbamoylamino)-5-oxopentanoic acid
maximal inhibition of 40% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
5-(carbamoylthio)pentanoic acid
maximal inhibition of 65% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
5-butylpyridine-2-carboxylic acid
maximal inhibition of 5% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
7-ethoxy-6,7-dioxoheptanoic acid
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
Benzoic acid
maximal inhibition of 2% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
carboxycarbonyl-benzoic acid
maximal inhibition of 22% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 4-((2-amino-2-oxoethyl)sulfinyl)butanoate
maximal inhibition of 31% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 4-((2-amino-2-oxoethyl)sulfonyl)butanoate
maximal inhibition of 12% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 4-((2-amino-2-oxoethyl)thio)butanoate
maximal inhibition of 21% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl 5-(carbamoylsulfanyl)pentanoate
maximal inhibition of 34% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
ethyl [(4-amino-4-oxobutyl)(methyl)amino](oxo)acetate
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
heptanedioic acid
maximal inhibition of 10% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
hydroxy[4-(methoxycarbonyl)phenyl]acetic acid
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methoxycarbonyl-phenyloxoacetic acid
maximal inhibition of 29% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 3-oxohexanoate
maximal inhibition of 5% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 4-(2,4,5-trioxoimidazolidin-1-yl)butanoate
maximal inhibition of 38% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 4-[(2-ethoxy-2-oxoethyl)(methyl)amino]butanoate
maximal inhibition of 42% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 4-[amino(oxo)acetyl]benzoate
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 5-(carbamoylamino)-5-oxopentanoate
maximal inhibition of 65% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 6-oxo-6-(2H-tetrazol-5-yl)hexanoate
maximal inhibition of 35% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 7-amino-6,7-dioxoheptanoate
maximal inhibition of 24% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
methyl 7-amino-6-hydroxy-7-oxoheptanoate
maximal inhibition of 28% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
additional information
molecular descriptors analysis shows that ligands with polar surface area of 91.7 A are likely inhibitors
Mycobacterium tuberculosis
4.3.3.7
N1-(4-amino-4-oxobutyl)-N1-methylethanediamide
maximal inhibition of 40% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
4.3.3.7
[(4-amino-4-oxobutyl)(methyl)amino](oxo)acetic acid
maximal inhibition of 44% (highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor at a given concentration of other substrates pyruvate 0.5 mM and 0.4 mM L-aspartate-4-semialdehyde), in a coupled assay with recombinant dihydrodipicolinate reductase
Mycobacterium tuberculosis
Ki Value [mM] (protein specific)
EC Number
Ki Value [mM]
Ki Value maximum [mM]
Inhibitor
Commentary
Organism
Structure
4.3.3.7
0.021
-
2-oxopimelate
pH 7.4, 37C
Mycobacterium tuberculosis
Purification (Commentary) (protein specific)
EC Number
Commentary
Organism
4.3.3.7
-
Mycobacterium tuberculosis
Substrates and Products (Substrate) (protein specific)
EC Number
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
1.17.1.8
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + NADPH + H+
-
746457
Mycobacterium tuberculosis
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + NADP+ + H2O
-
-
-
?
1.17.1.8
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + NADPH + H+
-
746457
Mycobacterium tuberculosis H37Rv
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + NADP+ + H2O
-
-
-
?
4.3.3.7
pyruvate + L-aspartate-4-semialdehyde
-
746457
Mycobacterium tuberculosis
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + H2O
-
-
-
?
4.3.3.7
pyruvate + L-aspartate-4-semialdehyde
-
746457
Mycobacterium tuberculosis H37Rv
(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate + H2O
-
-
-
?